My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 2447

    1.

    Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.

    Meier JJ, Kemmeries G, Holst JJ, Nauck MA.

    Diabetes. 2005 Jul;54(7):2212-8.PMID: 15983224 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

    Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH.

    Am J Physiol. 1997 Nov;273(5 Pt 1):E981-8.PMID: 9374685 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

    Nauck MA, Wollschläger D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B.

    Diabetologia. 1996 Dec;39(12):1546-53.PMID: 8960841 [PubMed - indexed for MEDLINE]Related articles

    4.

    Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.

    Gutniak MK, Juntti-Berggren L, Hellström PM, Guenifi A, Holst JJ, Efendic S.

    Diabetes Care. 1996 Aug;19(8):857-63.PMID: 8842604 [PubMed - indexed for MEDLINE]Related articles

    5.

    Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

    Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA.

    J Clin Endocrinol Metab. 1996 Jan;81(1):327-32.PMID: 8550773 [PubMed - indexed for MEDLINE]Related articles

    6.

    alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.

    Hücking K, Kostic Z, Pox C, Ritzel R, Holst JJ, Schmiegel W, Nauck MA.

    Diabet Med. 2005 Apr;22(4):470-6.PMID: 15787675 [PubMed - indexed for MEDLINE]Related articles

    7.

    Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.

    Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

    Regul Pept. 2003 Jul 15;114(2-3):115-21.PMID: 12832099 [PubMed - indexed for MEDLINE]Related articles

    8.

    Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.

    Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W.

    J Clin Endocrinol Metab. 1993 Apr;76(4):912-7.PMID: 8473405 [PubMed - indexed for MEDLINE]Related articles

    9.

    Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.

    Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz B.

    Diabetes. 2004 Mar;53(3):654-62.PMID: 14988249 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Effect of glucagon on carbohydrate-mediated secretion of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-36 amide) (GLP-1).

    Ranganath L, Schaper F, Gama R, Morgan L, Wright J, Teale D, Marks V.

    Diabetes Metab Res Rev. 1999 Nov-Dec;15(6):390-4.PMID: 10634963 [PubMed - indexed for MEDLINE]Related articles

    11.

    The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.

    Meier JJ, Gethmann A, Nauck MA, Götze O, Schmitz F, Deacon CF, Gallwitz B, Schmidt WE, Holst JJ.

    Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1118-23. Epub 2006 Jan 10.PMID: 16403774 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

    Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W.

    J Clin Invest. 1993 Jan;91(1):301-7.PMID: 8423228 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.

    Näslund E, Gutniak M, Skogar S, Rössner S, Hellström PM.

    Am J Clin Nutr. 1998 Sep;68(3):525-30.PMID: 9734726 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM.

    Dupre J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P, McDonald TJ.

    Diabetes. 1995 Jun;44(6):626-30.PMID: 7789625 [PubMed - indexed for MEDLINE]Related articles

    15.

    Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.

    Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hüfner M, Schmiegel WH.

    J Clin Endocrinol Metab. 2002 Mar;87(3):1239-46.PMID: 11889194 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Gastric inhibitory polypeptide does not inhibit gastric emptying in humans.

    Meier JJ, Goetze O, Anstipp J, Hagemann D, Holst JJ, Schmidt WE, Gallwitz B, Nauck MA.

    Am J Physiol Endocrinol Metab. 2004 Apr;286(4):E621-5. Epub 2003 Dec 16.PMID: 14678954 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.

    Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA.

    J Clin Endocrinol Metab. 2003 Jun;88(6):2719-25.PMID: 12788879 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes.

    Gutniak MK, Svartberg J, Hellström PM, Holst JJ, Adner N, Ahrén B.

    J Intern Med. 2001 Jul;250(1):81-7.PMID: 11454146 [PubMed - indexed for MEDLINE]Related articles

    19.

    GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans.

    Näslund E, Bogefors J, Skogar S, Grybäck P, Jacobsson H, Holst JJ, Hellström PM.

    Am J Physiol. 1999 Sep;277(3 Pt 2):R910-6.PMID: 10484511 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.

    Nauck MA, El-Ouaghlidi A, Gabrys B, Hücking K, Holst JJ, Deacon CF, Gallwitz B, Schmidt WE, Meier JJ.

    Regul Pept. 2004 Nov 15;122(3):209-17.PMID: 15491793 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity